BHLHE22 and endometrial cancer: The methylation profiles from cervical scrapings of endometrial cancer patients (n = 50) and healthy controls (n = 56) were compared, and the results showed that hypermethylation of CDO1 alone, CELF4 alone, BHLHE22 alone, and any two positive among CDO1/CELF4/BHLHE22 had a sensitivity of 82%, 96%, 83.7%, and 91.8%, respectively, in screening for endometrial cancer in post-menopausal patients [13].